BRAF and glycogen storage disease VI: In this study, one patient with confirmed BRAF V600E mutation and relapsed myeloma with extensive extramedullary disease who was refractory to all approved therapeutic options rapidly and durably responded to low doses of the mutation-specific BRAF inhibitor vermurafenib 31.